Nuveen’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Nuveen’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,906	Closed	-$68K	–	3596
2021 Q1	$68K	Hold	10,906	–	–	﹤0.01%	3295
2020 Q4	$86K	Buy	+10,906	New	+$100K	﹤0.01%	3241

Other funds holding MTCR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's MTCR Position: Q2 2021 in Review

Nuveen sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2021, closing a stake of 10,906 shares — an estimated $68K sold.

Nuveen first reported a position in MTCR in Q4 2020 and held it in 2 quarters. The position peaked at $86K in Q4 2020. 42 funds tracked by Wall St. Rank hold MTCR as of Q2 2021.

Nuveen reported no remaining Metacrine, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Nuveen sold 10,906 Metacrine, Inc. Common Stock shares in Q2 2021, an estimated $68K.
Nuveen first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
Nuveen's Metacrine, Inc. Common Stock position peaked at $86K in Q4 2020.
42 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.